Boston goes exclusive on paclitaxel stent rights
This article was originally published in Clinica
Executive Summary
Boston Scientific now holds the exclusive rights to technology it uses in its blockbuster Taxus Express2 drug-eluting stent. The new arrangement comes after Boston's one-time rival, Cook, decided to stop pursuing the lucrative but highly competitive coronary vascular stent market and sold back its co-exclusive rights to the licensor for $25m.